AARP (2021)

A small study has found that the experimental drug donanemab may slow cognitive decline in Alzheimer's patients. It joins others that show promise.



Comments

No comments yet. Be the first to comment!

Related Chunks

Related chunks with this resource

This Article can be found in 1 chunk
research and new advances in the battle against Alzheimer’s

MORE RESOURCES FROM SOURCE

More in FoundryBase from   AARP